Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Melanoma

  Free Subscription

Articles published in J Invest Dermatol

Retrieve available abstracts of 98 articles:
HTML format

Single Articles

    November 2022
  1. DONG B, Simonson L, Vold S, Oldham E, et al
    Frizzled 6 promotes melanoma cell invasion but not proliferation by regulating canonical Wnt signaling and EMT.
    J Invest Dermatol. 2022 Nov 8. pii: S0022-202X(22)02660.
    PubMed     Abstract available

  2. ABDELAZEEM B, Abbas KS, Shehata J, Alfaar AS, et al
    Increased Risk of Subsequent Skin Melanoma in Patients with Retinoblastoma: SEER-Based Results.
    J Invest Dermatol. 2022;142:3123-3125.

  3. HARMS PW, Chan MP, Bresler SC, Andea AA, et al
    Comment on "An Epidemiologic Analysis of Melanoma Overdiagnosis in the United States, 1975-2017".
    J Invest Dermatol. 2022;142:3120-3122.

    October 2022
  4. DIVINCENZO MJ, Schwarz E, Ren C, Barricklow Z, et al
    Expression patterns of microRNAs and associated target genes in ulcerated primary cutaneous melanoma.
    J Invest Dermatol. 2022 Oct 3. pii: S0022-202X(22)02640.
    PubMed     Abstract available

    September 2022
  5. CHAKRABORTY A, Perez M, Carroll JD, Antonopoulos A, et al
    Hypoxia controls the glycome signature and galectin-8 - ligand axis to promote pro-tumorigenic properties of metastatic melanoma.
    J Invest Dermatol. 2022 Sep 26. pii: S0022-202X(22)01931.
    PubMed     Abstract available

  6. KREUGER IZM, Slieker RC, van Groningen T, van Doorn R, et al
    Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma.
    J Invest Dermatol. 2022 Sep 16. pii: S0022-202X(22)01769.
    PubMed     Abstract available

  7. LASHERAS-OTERO I, Feliu I, Maillo A, Moreno H, et al
    The regulators of peroxisomal acyl-carnitine shuttle CROT and CRAT promote metastasis in melanoma.
    J Invest Dermatol. 2022 Sep 1. pii: S0022-202X(22)01890.
    PubMed     Abstract available

    August 2022
  8. JOUR G, Illa-Bochaca I, Ibrahim M, Donnelly D, et al
    Genomic and transcriptomic analyses of NF1-mutant melanoma identify potential targeted approach for treatment.
    J Invest Dermatol. 2022 Aug 18. pii: S0022-202X(22)01780.
    PubMed     Abstract available

    July 2022
  9. CHOUSAKOS E, Kose K, Kurtansky NR, Dusza SW, et al
    J Invest Dermatol. 2022 Jul 13. pii: S0022-202X(22)01663.
    PubMed     Abstract available

    June 2022
  10. WIGGINS JM, Ali S, Polsky D
    Cell-Free DNA in Dermatology Research.
    J Invest Dermatol. 2022;142:1523-1528.
    PubMed     Abstract available

    May 2022
  11. VERGANI E, Busico A, Dugo M, Devecchi A, et al
    Genetic layout of melanoma lesions associates to BRAF/MEK-targeted therapy resistance and to transcriptional profiles.
    J Invest Dermatol. 2022 May 25. pii: S0022-202X(22)00400.
    PubMed     Abstract available

  12. KAINULAINEN K, Takabe P, Heikkinen S, Aaltonen N, et al
    M1 macrophages induce pro-tumor inflammation in melanoma cells via TNFR-NF-kappaB signaling.
    J Invest Dermatol. 2022 May 14. pii: S0022-202X(22)00393.
    PubMed     Abstract available

    April 2022
  13. LIU Y, Chi W, Tao L, Wang G, et al
    Ablation of H(+)/glucose Exporter SLC45A2 Enhances Melanosomal Glycolysis to Inhibit Melanin Biosynthesis and Promote Melanoma Metastasis.
    J Invest Dermatol. 2022 Apr 22. pii: S0022-202X(22)00301.
    PubMed     Abstract available

  14. CHANG GA, Robinson E, Wiggins JM, Zhang Y, et al
    Associations between TERT promoter mutations and survival in superficial spreading and nodular melanomas in a large prospective patient cohort.
    J Invest Dermatol. 2022 Apr 22. pii: S0022-202X(22)00304.
    PubMed     Abstract available

  15. LEE KJ, Stark MS
    In Vivo Melanoma Cell Morphology and Tumor Aggressiveness: The Promise of Reflectance Confocal Microscopy in Reducing Unnecessary Excisions.
    J Invest Dermatol. 2022 Apr 2. pii: S0022-202X(22)00079.

    March 2022
  16. BRENNER E, Rocken M
    A Commotion in the Skin: Developing Melanoma Immunotherapies.
    J Invest Dermatol. 2022 Mar 23. pii: S0022-202X(22)00097.
    PubMed     Abstract available

  17. FRANTZ WT, Ceol CJ
    Research Techniques Made Simple: Zebrafish Models for Human Dermatologic Disease.
    J Invest Dermatol. 2022;142.
    PubMed     Abstract available

    February 2022
  18. KAMADA H, Yasuhira S, Shibazaki M, Amano H, et al
    DUSP4 inactivation leads to reduced ERK activity via the upregulation of DUSP6 in melanoma cells.
    J Invest Dermatol. 2022 Feb 18. pii: S0022-202X(22)00126.
    PubMed     Abstract available

  19. YEPES S, Tucker MA, Koka H, Xiao Y, et al
    Integrated Analysis of Co-expression and Exome Sequencing to Prioritize Susceptibility Genes for Familial Cutaneous Melanoma.
    J Invest Dermatol. 2022 Feb 15. pii: S0022-202X(22)00118.
    PubMed     Abstract available

  20. LAZAR I, Clement E, Carrie L, Esteve D, et al
    Adipocyte extracellular vesicles decrease p16(INK4A) in melanoma: an additional link between obesity and cancer.
    J Invest Dermatol. 2022 Feb 9. pii: S0022-202X(22)00099.
    PubMed     Abstract available

  21. WANG D, Fu Z, Gao L, Zeng J, et al
    Increased IRF9-STAT2 signaling leads to adaptive resistance toward targeted therapy in melanoma by restraining GSDME-dependent pyroptosis.
    J Invest Dermatol. 2022 Feb 8. pii: S0022-202X(22)00096.
    PubMed     Abstract available

  22. LI Y, Wu J, Tian Y, Zhu Q, et al
    Med1 downregulation contributes to TGF-beta-induced metastasis by inhibiting Smad2 ubiquitination degradation in cutaneous melanoma.
    J Invest Dermatol. 2022 Feb 4. pii: S0022-202X(22)00081.
    PubMed     Abstract available

  23. EMRAN AA, Fisher DE
    Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma.
    J Invest Dermatol. 2022 Feb 4. pii: S0022-202X(21)02378.
    PubMed     Abstract available

  24. AZIN M, Demehri S
    STK11 Loss: A Novel Mechanism for Melanoma Metastasis with Therapeutic Implications.
    J Invest Dermatol. 2022 Feb 4. pii: S0022-202X(21)02345.
    PubMed     Abstract available

  25. GUIDA S, Guida G, Goding CR
    MC1R Functions, Expression, and Implications for Targeted Therapy.
    J Invest Dermatol. 2022;142:293-302.
    PubMed     Abstract available

  26. XU G, Luo Y, Wu W, Liu X, et al
    The Evolution of Acquired Resistance to BRAF(V600E) kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular Remodeling.
    J Invest Dermatol. 2022;142:445-458.
    PubMed     Abstract available

    January 2022
  27. OLSEN CM, Whiteman DC
    Cutaneous Melanoma in White Americans: A Tale of Two Epidemics.
    J Invest Dermatol. 2022 Jan 30. pii: S0022-202X(22)00003.
    PubMed     Abstract available

  28. CHU YS, Lee S, Lee SG, Chung KY, et al
    Deep Learning Algorithms for Predicting Breslow Thickness from Dermoscopic Images of Acral Lentiginous Melanomas.
    J Invest Dermatol. 2022 Jan 12. pii: S0022-202X(22)00008.

  29. BUSTOS MA, Hoon DSB
    Prognostic Utility of CpG Island Hypermethylated Phenotype in Early-Stage Invasive Primary Melanomas.
    J Invest Dermatol. 2022 Jan 11. pii: S0022-202X(21)02629.
    PubMed     Abstract available

  30. MARCONI A, Quadri M, Farnetani F, Ciardo S, et al
    In Vivo Melanoma Cell Morphology Reflects Molecular Signature and Tumor Aggressiveness.
    J Invest Dermatol. 2022 Jan 7. pii: S0022-202X(21)02683.
    PubMed     Abstract available

  31. BECHMANN N, Calsina B, Richter S, Pietzsch J, et al
    Therapeutic Potential of Nitric Oxide releasing Selective Estrogen Receptor Modulators (NO-SERMs) in Malignant Melanoma.
    J Invest Dermatol. 2022 Jan 3. pii: S0022-202X(21)02691.
    PubMed     Abstract available

    December 2021
  32. KUMPER M, Hessenthaler S, Zamek J, Niland S, et al
    J Invest Dermatol. 2021 Dec 27. pii: S0022-202X(21)02633.
    PubMed     Abstract available

  33. FANE ME, Chhabra Y, Spoerri L, Simmons JL, et al
    Reciprocal regulation of BRN2 and NOTCH1/2 signaling synergistically drives melanoma cell migration and invasion.
    J Invest Dermatol. 2021 Dec 24. pii: S0022-202X(21)02630.
    PubMed     Abstract available

  34. WANG Y, Ramachandran V, Sui D, Xu K, et al
    Evaluation of Plasma Interleukin-6 in Melanoma Patients as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker.
    J Invest Dermatol. 2021 Dec 21. pii: S0022-202X(21)02627.

  35. MUKHERJEE N, Dart CR, Amato CM, Honig-Frand A, et al
    Expression differences in BCL2 family members between uveal and cutaneous melanomas account for varying sensitivity to BH3 mimetics.
    J Invest Dermatol. 2021 Dec 20. pii: S0022-202X(21)02617.
    PubMed     Abstract available

  36. KURTANSKY NR, Dusza SW, Halpern AC, Hartman RI, et al
    An Epidemiologic Analysis of Melanoma Overdiagnosis in the United States, 1975-2017.
    J Invest Dermatol. 2021 Dec 10. pii: S0022-202X(21)02610.
    PubMed     Abstract available

  37. HRISTOVA DM, Fukumoto T, Takemori C, Gao L, et al
    J Invest Dermatol. 2021 Dec 6. pii: S0022-202X(21)02600.
    PubMed     Abstract available

  38. CHHABRA G, Ahmad N
    BRAF Inhibitors in Melanoma Management: When Friends Become Foes.
    J Invest Dermatol. 2021 Dec 3. pii: S0022-202X(21)02485.
    PubMed     Abstract available

    November 2021
  39. CONWAY K, Tsai YS, Edmiston SN, Parker JS, et al
    Characterization of the CpG island hypermethylated phenotype (CIMP) subclass in primary melanomas.
    J Invest Dermatol. 2021 Nov 26. pii: S0022-202X(21)02531.
    PubMed     Abstract available

  40. MA B, Anandasabapathy N
    Immune Checkpoint Blockade and Skin Toxicity Pathogenesis.
    J Invest Dermatol. 2021 Nov 26. pii: S0022-202X(21)02308.
    PubMed     Abstract available

  41. LIYANAGE U, MacGregor S, Bishop DT, Shi J, et al
    Multi-trait genetic analysis identifies auto-immune loci associated with cutaneous melanoma.
    J Invest Dermatol. 2021 Nov 20. pii: S0022-202X(21)02513.
    PubMed     Abstract available

  42. DEL ROSSO M, Fibbi G, Laurenzana A, Margheri F, et al
    A Possible Role for PAI-1 Blockade in Melanoma Immunotherapy.
    J Invest Dermatol. 2021;141:2566-2568.
    PubMed     Abstract available

    October 2021
  43. DZUNG A, Saltari A, Tiso N, Lyck R, et al
    STK11 Prevents Invasion Through STAT3/5 and FAK Repression in Cutaneous Melanoma.
    J Invest Dermatol. 2021 Oct 29. pii: S0022-202X(21)02466.
    PubMed     Abstract available

  44. KIM RH, Nomikou S, Coudray N, Jour G, et al
    Deep learning and pathomics analyses reveal cell nuclei as important features for mutation prediction of BRAF-mutated melanomas.
    J Invest Dermatol. 2021 Oct 29. pii: S0022-202X(21)02405.
    PubMed     Abstract available

  45. KIURU M, Kriner MA, Wong S, Zhu G, et al
    High-plex spatial RNA profiling reveals cell type-specific biomarker expression during melanoma development.
    J Invest Dermatol. 2021 Oct 23. pii: S0022-202X(21)02370.
    PubMed     Abstract available

  46. AHMED F, Tseng HY, Ahn A, Gunatilake D, et al
    Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor resistant melanoma.
    J Invest Dermatol. 2021 Oct 22. pii: S0022-202X(21)02384.
    PubMed     Abstract available

  47. AL RAHMOUN M, Ghiasvand R, Cairat M, Mahamat-Saleh Y, et al
    Statin Use and Skin Cancer Risk: A Prospective Cohort Study.
    J Invest Dermatol. 2021 Oct 22. pii: S0022-202X(21)02382.
    PubMed     Abstract available

  48. NJAUW CN, Ji Z, Pham DM, Simoneau A, et al
    Oncogenic KIT Induces Replication stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma.
    J Invest Dermatol. 2021 Oct 20. pii: S0022-202X(21)02347.
    PubMed     Abstract available

  49. JANDOVA J, Wondrak GT
    Vemurafenib drives EMT gene expression in BRAFi-resistant BRAF(V600E)/NRAS(Q61K) melanoma enhancing tumor growth and metastasis in a bioluminescent murine model.
    J Invest Dermatol. 2021 Oct 20. pii: S0022-202X(21)02368.
    PubMed     Abstract available

  50. NAGORE E, Viros A, Kumar R
    Positive Attributes of Anti-TERT CD4 T-Helper Type 1 Immune Responses in Melanoma.
    J Invest Dermatol. 2021 Oct 16. pii: S0022-202X(21)02269.
    PubMed     Abstract available

  51. CHILIBROSTE S, Monaco A, Plata MC, Vola M, et al
    Preclinical evaluation of LVR01 attenuated Salmonella as neoadjuvant intralesional therapy in combination with chemotherapy for melanoma treatment.
    J Invest Dermatol. 2021 Oct 15. pii: S0022-202X(21)02317.
    PubMed     Abstract available

    September 2021
  52. CHHABRA G, Singh CK, Guzman-Perez G, Ndiaye MA, et al
    Anti-melanoma effects of concomitant inhibition of SIRT1 and SIRT3 in Braf(V600E)/Pten(NULL) mice.
    J Invest Dermatol. 2021 Sep 28. pii: S0022-202X(21)02223.
    PubMed     Abstract available

  53. XU T, Dai J, Tang L, Yang L, et al
    EZH2 inhibitor enhances the STING agonist-induced antitumor immunity in melanoma.
    J Invest Dermatol. 2021 Sep 24. pii: S0022-202X(21)02227.
    PubMed     Abstract available

  54. EMMONS MF, Smalley KSM
    Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma.
    J Invest Dermatol. 2021 Sep 23. pii: S0022-202X(21)01436.
    PubMed     Abstract available

  55. ADELMANN CH, Rachmin I, Fisher DE
    MFN2 Stabilization: A Bridge for Endoplasmic Reticulum Stress Sensitivity in Melanoma.
    J Invest Dermatol. 2021 Sep 23. pii: S0022-202X(21)01224.
    PubMed     Abstract available

  56. GUTIERREZ-SEIJO A, Garcia-Martinez E, Barrio-Alonso C, Parra-Blanco V, et al
    Activin A sustains the metastatic phenotype of tumor associated macrophages and is a prognostic marker in human cutaneous melanoma.
    J Invest Dermatol. 2021 Sep 6. pii: S0022-202X(21)02171.
    PubMed     Abstract available

    August 2021
  57. DAS I, Tuominen R, Helleday T, Hansson J, et al
    Co-expression of MTH1 and PMS2 is associated with advanced disease and disease progression after therapy in melanoma.
    J Invest Dermatol. 2021 Aug 18. pii: S0022-202X(21)01689.

  58. NARDIN C, Laheurte C, Puzenat E, Boullerot L, et al
    Naturally occurring Telomerase-specific CD4 T cell Immunity in Melanoma.
    J Invest Dermatol. 2021 Aug 2. pii: S0022-202X(21)01667.
    PubMed     Abstract available

    July 2021
  59. MONTAUDIE H, Sormani L, Dadone-Montaudie B, Heim M, et al
    CLEC12B decreases melanoma proliferation by repressing STAT3.
    J Invest Dermatol. 2021 Jul 23. pii: S0022-202X(21)01464.
    PubMed     Abstract available

  60. QUADRI M, Comitato A, Palazzo E, Tiso N, et al
    Activation of PKG restricts melanoma growth and invasion by interfering with the EGF/EGFR pathway.
    J Invest Dermatol. 2021 Jul 12. pii: S0022-202X(21)01420.
    PubMed     Abstract available

  61. WANG S, Yi X, Wu Z, Guo S, et al
    CAMKK2 defines ferroptosis sensitivity of melanoma cells by regulating AMPK-Nrf2 pathway.
    J Invest Dermatol. 2021 Jul 6. pii: S0022-202X(21)01416.
    PubMed     Abstract available

  62. PATMANATHAN SN, Tong BT, Jackie Teo JH, Jonathan Ting YZ, et al
    A PDZ Protein GIPC3 Positively Modulates Hedgehog Signaling and Melanoma Growth.
    J Invest Dermatol. 2021 Jul 2. pii: S0022-202X(21)01414.
    PubMed     Abstract available

  63. CHU EY, Takeshita J, Ming ME
    Shedding Light on Disparities in Melanoma Care.
    J Invest Dermatol. 2021;141:1625-1626.
    PubMed     Abstract available

    June 2021
  64. SHEINBOIM D, Parikh S, Parikh R, Menuchin A, et al
    Slow transcription of the 99a/let-7c/125b-2 cluster results in differential miRNA expression and promotes melanoma phenotypic plasticity.
    J Invest Dermatol. 2021 Jun 26. pii: S0022-202X(21)01406.
    PubMed     Abstract available

  65. KLEINERMAN RA, Schonfeld SJ, Abramson DH, Francis JH, et al
    Increased risk of skin cancer in 1851 long-term retinoblastoma survivors.
    J Invest Dermatol. 2021 Jun 18. pii: S0022-202X(21)01334.
    PubMed     Abstract available

    May 2021
  66. WANG H, Yi X, Guo S, Wang S, et al
    The XBP1-MARCH5-MFN2 axis confers ER stress resistance by coordinating mitochondrial fission and mitophagy in melanoma.
    J Invest Dermatol. 2021 May 25. pii: S0022-202X(21)01243.
    PubMed     Abstract available

  67. TSENG YJ, Lee CH, Chen WY, Yang JL, et al
    Inhibition of plasminogen activator inhibitor-1 blocks programmed death ligand 1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.
    J Invest Dermatol. 2021 May 14. pii: S0022-202X(21)01230.
    PubMed     Abstract available

  68. JI Z, Njauw CN, Guhan S, Kumar R, et al
    Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition.
    J Invest Dermatol. 2021;141:1317-1324.
    PubMed     Abstract available

    April 2021
  69. MUNIZ TP, Sorotsky H, Kanjanapan Y, Rose AAN, et al
    Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor-like Melanoma.
    J Invest Dermatol. 2021 Apr 5. pii: S0022-202X(21)01132.
    PubMed     Abstract available

  70. DU-HARPUR X, Arthurs C, Ganier C, Woolf R, et al
    Clinically Relevant Vulnerabilities of Deep Machine Learning Systems for Skin Cancer Diagnosis.
    J Invest Dermatol. 2021;141:916-920.

    March 2021
  71. HARBERS FN, Thier B, Stupia S, Zhu S, et al
    Melanoma differentiation trajectories determine sensitivity towards pre-existing CD8(+) tumor-infiltrating lymphocytes.
    J Invest Dermatol. 2021 Mar 30. pii: S0022-202X(21)01124.
    PubMed     Abstract available

  72. AL EMRAN A, Tseng HY, Gunatilake D, Cook SJ, et al
    A combination of epigenetic BET and CDK9 inhibitors for treatment of human melanoma.
    J Invest Dermatol. 2021 Mar 26. pii: S0022-202X(21)01121.
    PubMed     Abstract available

  73. GUHAN SM, Shaughnessy M, Rajadurai A, Taylor M, et al
    The molecular context of vulnerability for CDK9 suppression in triple wild-type melanoma.
    J Invest Dermatol. 2021 Mar 18. pii: S0022-202X(21)00977.
    PubMed     Abstract available

  74. PERES J, Damerell V, Chauhan J, Popovic A, et al
    TBX3 promotes melanoma migration by transcriptional activation of ID1 which prevents activation of E-cadherin by MITF.
    J Invest Dermatol. 2021 Mar 17. pii: S0022-202X(21)01001.
    PubMed     Abstract available

  75. MARCHETTI MA, Nanda JK, Mancebo SE, Dusza SW, et al
    Real-world application of a non-invasive 2-gene expression test for melanoma diagnosis.
    J Invest Dermatol. 2021 Mar 17. pii: S0022-202X(21)01018.

  76. FREUND L, Kjaer SK, Guleria S, Albieri V, et al
    Use of fertility drugs and risk of malignant melanoma: results from a large Danish population-based cohort study.
    J Invest Dermatol. 2021 Mar 16. pii: S0022-202X(21)01022.
    PubMed     Abstract available

  77. TIKOO S, Jain R, Tomasetig F, On K, et al
    Amelanotic B16-F10 melanoma compatible with advanced 3-D imaging modalities.
    J Invest Dermatol. 2021 Mar 3. pii: S0022-202X(21)00156.

    February 2021
  78. GRAMANN AK, Frantz WT, Dresser K, Ferreira Gomes CB, et al
    BMP signaling promotes neural crest identity and accelerates melanoma onset.
    J Invest Dermatol. 2021 Feb 18. pii: S0022-202X(21)00150.

  79. KIM KB, Soroceanu L, de Semir D, Millis SZ, et al
    Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
    J Invest Dermatol. 2021 Feb 18. pii: S0022-202X(21)00155.
    PubMed     Abstract available

  80. KOIKOV L, Starner RJ, Swope VB, Upadhyay P, et al
    Development of hMC1R Selective Small Agonists for Sunless Tanning and Prevention of Genotoxicity of UV in Melanocytes.
    J Invest Dermatol. 2021 Feb 17. pii: S0022-202X(21)00117.
    PubMed     Abstract available

  81. SCHEEREN FA, van Doorn R
    Inhibition of the Epigenetic Reader BRD4 Reduces SIRPalpha-Mediated Phagocytosis and Melanoma Invasion.
    J Invest Dermatol. 2021;141:252-254.
    PubMed     Abstract available

  82. OSTROWSKI SM, Fisher DE
    The Melanocyte Lineage Factor miR-211 Promotes BRAF(V600E) Inhibitor Resistance.
    J Invest Dermatol. 2021;141:250-252.
    PubMed     Abstract available

    January 2021
  83. SHAH P, Shao Y, Geller AC, Polsky D, et al
    Late stage melanoma in New York State: associations with socioeconomic factors and healthcare access at the county level.
    J Invest Dermatol. 2021 Jan 28. pii: S0022-202X(21)00031.
    PubMed     Abstract available

  84. YU WY, Hill ST, Chan ER, Pink JJ, et al
    Computational drug repositioning identifies statins as a modifier of prognostic genetic expression signatures and metastatic behavior in melanoma.
    J Invest Dermatol. 2021 Jan 5. pii: S0022-202X(20)32413.
    PubMed     Abstract available

  85. ZHOU Q, Kim SH, Perez-Lorenzo R, Liu C, et al
    Phenformin Promotes Keratinocyte Differentiation via the Calcineurin/NFAT Pathway.
    J Invest Dermatol. 2021;141:152-163.
    PubMed     Abstract available

    December 2020
  86. TRAVNICKOVA J, Patton EE
    Deciphering melanoma cell states and plasticity with zebrafish models.
    J Invest Dermatol. 2020 Dec 16. pii: S0022-202X(20)32400.
    PubMed     Abstract available

  87. FUKUMOTO T, Lin J, Fatkhutdinov N, Liu P, et al
    ARID2 deficiency correlates with the response to immune checkpoint blockade in melanoma.
    J Invest Dermatol. 2020 Dec 14. pii: S0022-202X(20)32396.
    PubMed     Abstract available

    November 2020
  88. DOEPNER M, Lee IY, Ridky TW
    Drug Resistant Melanoma May Be Vulnerable to Inhibitors of Serine Synthesis.
    J Invest Dermatol. 2020;140:2114-2116.
    PubMed     Abstract available

    October 2020
  89. POIZEAU F, Kerbrat S, Happe A, Rault C, et al
    Patients with metastatic melanoma receiving anticancer drugs: changes in overall survival, 2010-2017.
    J Invest Dermatol. 2020 Oct 10. pii: S0022-202X(20)32138.
    PubMed     Abstract available

    September 2020
  90. HUANG SW, Wang ST, Chang SH, Chuang KC, et al
    Imiquimod Exerts Antitumor Effects by Inducing Immunogenic Cell Death and Is Enhanced by the Glycolytic Inhibitor 2-Deoxyglucose.
    J Invest Dermatol. 2020;140:1771-1783.
    PubMed     Abstract available

    August 2020
  91. RODGERS CB, Broit N, Johansson PA, Pritchard AL, et al
    Attack of the Subclones: Accurate Detection of Mutational Heterogeneity in Bulk DNA from Tumors.
    J Invest Dermatol. 2020;140:1501-1503.
    PubMed     Abstract available

  92. QUAN VL, Zhang B, Zhang Y, Mohan LS, et al
    Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz Neoplasms.
    J Invest Dermatol. 2020;140:1599-1608.
    PubMed     Abstract available

    July 2020
  93. TETZLAFF MT, Farah M
    Without Missing a Beat: Absence of Cilia Informs the Diagnosis of Histopathologically Challenging Spitzoid Melanocytic Neoplasms.
    J Invest Dermatol. 2020;140:1320-1323.
    PubMed     Abstract available

    June 2020
  94. RAHMAN H, Kumar D, Liu T, Okwundu N, et al
    Aspirin protects melanocytes and keratinocytes against UVB-induced DNA damage in vivo.
    J Invest Dermatol. 2020 Jun 19. pii: S0022-202X(20)31684.
    PubMed     Abstract available

    April 2020
  95. HALSE H, Caramia F, McLean CA, Wang M, et al
    A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response.
    J Invest Dermatol. 2020;140:869-877.
    PubMed     Abstract available

    March 2020
  96. KIM E, Panzella L, Napolitano A, Payne GF, et al
    Redox Activities of Melanins Investigated by Electrochemical Reverse Engineering: Implications for their Roles in Oxidative Stress.
    J Invest Dermatol. 2020;140:537-543.
    PubMed     Abstract available

    January 2020
  97. LANG UE, Torres R, Cheung C, Vladar EK, et al
    Ciliation index is a useful diagnostic tool in challenging spitzoid melanocytic neoplasms.
    J Invest Dermatol. 2020 Jan 21. pii: S0022-202X(20)30038.
    PubMed     Abstract available

    December 2019
  98. CHITSAZAN A, Lambie D, Ferguson B, Handoko HY, et al
    Unexpected High Levels of BRN2/POU3F2 Expression in Human Dermal Melanocytic Nevi.
    J Invest Dermatol. 2019 Dec 24. pii: S0022-202X(19)33492.

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.